title: Infliximab as first-line therapy for severe Crohn's disease?
authors.affiliation: Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Illinois 60637, USA. rcohen@medicine.bsd.uchicago.edu
authors.forename: Russell D
authors.initials: RD
authors.lastname: Cohen
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab